SGX:40V - Singapore-eDev (SGD 0.041) 3 Followers SINGAPORE EDEVELOPMENT LTD
Sector: Finance, Industry: Real Estate Development

Add to WatchList

Set Alert


Global BioLife Inc.'s Naturally Modified Sugar Laetose(TM) Unveiled at Harvard Global Health Summit

24 Jul 2019 - ACN Newswire
SGX-listed Singapore eDevelopment Ltd ("SeD", SGX:40V) is pleased to announce the results of clinical trials conducted on Laetose(TM), a low-glycemic, naturally modified sugar, developed by its U.S. biomedical subsidiary Global BioLife Inc. ("Global BioLife").Clinical trial results show that Laetose ...
klse:4863 sgx:s68 sgx:40v

Global BioLife's new mosquito repellent formula performs well against mosquitos in independent testing

12 Jun 2019 - ACN Newswire
Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) ("SeD") wishes to announce today that its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife"), has independently tested a new mosquito repellent formula which performs well against mosquitos for six (6) to eight ...
sgx:s68 sgx:40v

Singapore eDevelopment (SGX:40V) Subsidiary, Global BioLife's 3F Antimicrobial Fragrance Shows Efficacy against Tuberculosis

28 Jan 2019 - ACN Newswire
Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) ("SeD") wishes to announce today that its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife") has a product known as 3F Antimicrobial Fragrance which shows efficacy against tuberculosis.Tuberculosis is the leading ...
sgx:40v

Singapore eDevelopment (SGX:40V) Subsidiary, Global BioLife, Proudly Announces Presentation of Parkinson's Research at Neuroscience 2018

7 Nov 2018 - ACN Newswire
Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) ("SeD"), through its subsidiary, Global BioLife Inc. ("Global BioLife") is pleased to announce that research of their promising drug platform, Linebacker, will be presented at Neuroscience 2018, the Annual Meeting for the International ...
sgx:s68 sgx:40v

Singapore eDevelopment Announces Corporate and Business Update

18 Jun 2018 - ACN Newswire
The Board of Directors of Singapore eDevelopment Limited ('SeD'; SGX 40V) wishes to provide shareholders an update on the Group's operations. 1 - Review of Core Businesses SGX Catalist-listed SeD (Stock Code: 40V) has strategically positioned itself as an investment holding company and embarked into ...
sgx:40v

Singapore eDevelopment Announces Corporate and Business Update

18 Jun 2018 - ACN Newswire
The Board of Directors of Singapore eDevelopment Limited ('SeD'; SGX 40V) wishes to provide shareholders an update on the Group's operations. 1 - Review of Core Businesses SGX Catalist-listed SeD (Stock Code: 40V) has strategically positioned itself as an investment holding company and embarked into ...
sgx:40v

Singapore Exchange-Listed Singapore eDevelopment Limited's U.S. Biomedical Subsidiary Global BioLife, Inc. Develops Low Glycemic Modified Sugar

31 May 2018 - ACN Newswire
Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife, Inc. ("Global BioLife"), has developed a low glycemic index, naturally modified sugar - Laetose - which has the potential to affect the world's sugar market. Global BioLife ...
sgx:s68 sgx:40v

Singapore eDevelopment (SGX:40V) biomedical subsidiary confirms LB2 efficacy against Ebola

1 Mar 2018 - ACN Newswire
Singapore eDevelopment (SGX: 40V; SeD) is pleased to announce biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for the study of new anti-viral drug LB2, part of its new universal therapeutic drug platform, Linebacker, which is designed to combat a range ...
sgx:40v

Singapore eDevelopment issues, transfers shares in US subsidiaries

24 Oct 2017 - Business Times Breaking News
SINGAPORE eDevelopment Ltd made several announcements after trading hours on Tuesday regarding its subsidiaries. Its wholly-owned indirect subsidiary Global BioMedical Inc (GBMI) will allot and issue 10 ordinary shares at US$0.001 per ordinary share to Tang Peihong, an executive director of GBMI.This ...
sgx:40v

Singapore-eDev: Names Biomedical Management Team That Includes Nobel Prize Nominee; Plans Research On Alzheimer's And Cancer.

13 Mar 2017 - ShareInvestor Express
Singapore-listed Singapore eDevelopment Ltd announced the appointment today of its biomedical division's senior management that will include a two-time Nobel Prize nominee, who will spearhead advanced research to develop a broad-spectrum therapeutic platform to address emerging pandemics such as Alzheimer's, ...
sgx:40v
Price Simulation

What happens (e.g. Current Yield) if the price becomes X?

My Notes

You currently do not have notes about this stock.




Dividends Tax Rate
Tax Rate (%)

Min Commission (SGD)


Past Transactions Add Transactions

You do not have past transactions for this stock.


Shared Portfolios Stats
All Shared Portfolios
0.5% holds 40V (1/200)
1.0% recent buy involves 40V (1/101)
0% recent sell involves 40V (0/54)

SGD 0.04 is median buy price (1/200)
SGD 0.04 is recent median buy price (1/101)
SGD NA is recent median sell price (0/54)

*recent means in the last 14 days.


Similar Stocks CITY DEVELOPMENTS LTD NCCPS

HWA HONG CORPORATION LIMITED

CAPITALAND LIMITED

DASIN RETAIL TRUST

UNITED OVERSEAS AUSTRALIA LTD